niacinamide has been researched along with Chronic Hepatitis B in 14 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 9.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 9.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 7.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 7.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 5.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 5.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 3.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 3.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| "Mean survival in hepatocellular carcinoma remains low." | 1.42 | Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon. ( Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sohn, W | 1 |
| Paik, YH | 1 |
| Cho, JY | 1 |
| Lim, HY | 2 |
| Ahn, JM | 1 |
| Sinn, DH | 1 |
| Gwak, GY | 1 |
| Choi, MS | 1 |
| Lee, JH | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Yang, Y | 1 |
| Wen, F | 1 |
| Li, J | 2 |
| Zhang, P | 1 |
| Yan, W | 1 |
| Hao, P | 1 |
| Xia, F | 1 |
| Bi, F | 1 |
| Li, Q | 1 |
| Qiu, X | 1 |
| Guo, W | 1 |
| Yan, B | 1 |
| Zhang, S | 1 |
| Park, JG | 1 |
| Loinaz Segurola, C | 1 |
| LIedó Navarro, JL | 1 |
| Burgos, Rde L | 1 |
| Martín Ríos, D | 1 |
| Ochando Cerdán, F | 1 |
| Alonso López, S | 1 |
| Martel Villagrán, J | 1 |
| Gutiérrez Garcia, ML | 1 |
| Fernandez Cebrián, JM | 1 |
| Fernández Rodríguez, C | 1 |
| Dika, IE | 1 |
| Harding, JJ | 1 |
| Abou-Alfa, GK | 1 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Yeganeh, M | 1 |
| Finn, RS | 1 |
| Saab, S | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Iavarone, M | 1 |
| Perrino, M | 1 |
| Viganò, M | 1 |
| Beck-Peccoz, P | 1 |
| Fugazzola, L | 1 |
| Villanueva, A | 1 |
| Newell, P | 1 |
| Hoshida, Y | 1 |
| Baek, KK | 1 |
| Kim, JH | 1 |
| Uhm, JE | 1 |
| Park, SH | 1 |
| Lee, J | 1 |
| Park, JO | 1 |
| Park, YS | 1 |
| Kang, WK | 1 |
| Nguyen, V | 1 |
| George, J | 1 |
| van der Poorten, D | 1 |
| Bruix, J | 1 |
| Raoul, JL | 1 |
| Sherman, M | 1 |
| Mazzaferro, V | 1 |
| Bolondi, L | 1 |
| Craxi, A | 1 |
| Galle, PR | 1 |
| Santoro, A | 1 |
| Beaugrand, M | 1 |
| Sangiovanni, A | 1 |
| Porta, C | 1 |
| Gerken, G | 1 |
| Marrero, JA | 1 |
| Nadel, A | 1 |
| Shan, M | 1 |
| Moscovici, M | 1 |
| Voliotis, D | 1 |
| Llovet, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for niacinamide and Chronic Hepatitis B
| Article | Year |
|---|---|
Hepatocellular carcinoma in patients with HIV.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Ch | 2017 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; | 2010 |
2 trials available for niacinamide and Chronic Hepatitis B
| Article | Year |
|---|---|
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Femal | 2015 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; F | 2012 |
8 other studies available for niacinamide and Chronic Hepatitis B
| Article | Year |
|---|---|
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Femal | 2015 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis | 2015 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2015 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chem | 2015 |
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hep | 2009 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, C | 2010 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular | 2012 |